- Home
- TLRY vs DNA Comparison
TLRY vs DNA Comparison
Compare TLRY & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLRY | DNA |
|---|---|---|
| Founded | N/A | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 562.3M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | TLRY | DNA |
|---|---|---|
| Price | $11.86 | $9.39 |
| Analyst Decision | Buy | Strong Sell |
| Analyst Count | 3 | 1 |
| Target Price | ★ $150.00 | $9.00 |
| AVG Volume (30 Days) | ★ 9.5M | 979.7K |
| Earning Date | 01-09-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $830,766,000.00 | $180,606,000.00 |
| Revenue This Year | $7.28 | N/A |
| Revenue Next Year | $4.51 | $7.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.31 | N/A |
| 52 Week Low | $3.51 | $5.00 |
| 52 Week High | $23.20 | $17.58 |
Technical Indicators
Market Signals| Indicator | TLRY | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 91.51 | 47.51 |
| Support Level | $7.10 | $8.56 |
| Resistance Level | $8.64 | $10.05 |
| Average True Range (ATR) | 0.62 | 0.55 |
| MACD | 0.78 | 0.27 |
| Stochastic Oscillator | 96.31 | 65.25 |
Price Performance
Historical ComparisonAbout TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mostly from alcohol.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.